Company intelligence / Profile preview
Delbert Pharma
- Ownership
- Private
- Employees
- ~22
- Development stage
- Commercial
Overview
Delbert Pharma specializes in maintaining market access to essential medicines at risk of disappearing. The company has commercialized several mature drugs across infectiology, pulmonology, neurology/psychiatry, oncology and hematology. It has obtained approvals for antibiotics against staphylococcal infections and treatments for bipolar disorder relapse prevention. Some programs are preclinical or focused on rare disease repositioning. The company became a mission-driven entity in France in September 2023 to formalize its commitment to public health needs.
- Therapeutic areas
- PulmonologyOncologyPsychiatryNeurologyInfectious Diseases
- Modalities
- Small moleculesInjectable drugsBronchial fluidifiers
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Delbert Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Delbert Pharma.